Career Point International Journal of Research (CPIJR)
©2022 CPIJR | Volume 4 | Issue 3 | ISSN : 2583-1895
December-2024 | DOI: https://doi.org/10.5281/zenodo.15054480

Transdermal Patches: Advanced Novel Drug Delivery System

[1]Anushka Mittal, [2]Mohammed Amaan, [3]Girish Kumar Vyas
[12]School of Pharmacy, Career Point University, Alynia, Kota, Rajasthan
[3]Associate Professor, School of Pharmacy, Career Point University, Alynia, Kota, Rajasthan
Email: anushkamittal77736@gmail.com , aslamamaan1908@gmail.com , girishvyas10@gmail.com

Abstracts:

Transdermal patch systems are one of the most advanced novel drug delivery systems that deliver therapeutic agents via skin and allows a controlled release of drugs directly into the circulatory system. This system avoids first pass hepatic metabolism and gastrointestinal degradation by this technique increases the drug bioavailability and reduce dosing frequency. The patches are easy to apply on the skin and reduce systemic side effects and has no restriction on patient's activity. The formulation of transdermal patches composed of various components, including drug reservoir, an adhesive layer and a rate controlling membrane these all play a significant role in ensuring the controlled and sustained release of drug.

This article explains mechanisms action of transdermal patches with the help of various types of patches such as matrix, reservoir, and drug-in-adhesive systems and iron exchange. Various benefits are Increased patient engagement, provide constant plasma drug levels, and minimize many side effects but challenges such as skin irritation, drug-induced hypersensitivity, and occlusion effects may be faced. Ongoing research and development efforts are focused on addressing existing challenges and expanding their applicability to a wider range of drugs and patient populations.

Keywords: Novel drug delivery system, first pass hepatic metabolism, drug reservoir, rate controlling membrane, drug-in-adhesive systems

Introduction:

Transdermal patches are thus a major innovation in the drug delivery system that provide a non-invasive besides being a controlled pathway for administering a therapeutic agent. These patches deliver active forms of drug substances through the skin as an option to oral/injectable system of taking medications. Due to enhanced drug release profile, higher bioavailability and a more rational approach for administration compared to conventional formulations especially for patients with chronic illnesses or disorders which are likely to be treated for long periods. A transdermal patch usually has backing layer, drug reservoir or matrix, adhesive layer as well as release liner. It sticks on the skin, and after hours, the drug slowly dissolves through the skin layers and into the blood circulation process. Absorption of the drug in the transdermal systems depends on

human skin and this mechanism is passive diffusion whereby the drug disperses from a areal concentration in the patch to a smaller concentration in the bloodstream. Effectiveness of diffusion rate may be regulated through the composition of the patch, thus the drug release occurs at a flat and consistent pace over time and that is the major strength of this system.

In transdermal drug delivery, penetration through the skin avoids GI tract and the first pass effect in the liver, which prevents the permeation of most drug molecules taken orally. This implies that drugs administered through the skin are more bioavailable compared to when the drugs are taken orally, and the will thus require less doses and give fewer side effects. Furthermore, transdermal patches provide a steady and well-regulated dosage of medication, with far less variation of drug levels, which are regarded important in diseases like hypertension, diabetes or chronic pain. Another strength of transdermal patches is patient compliance Another strength of transdermal patches is compliance that is related to patients or users. Conventional chemical medicine dosaging plans may demand patients to engorge on pills severally in one day or have injections from health facility to another, which are quite demanding to the elderly or chronic disease patients. The transdermal patches work well as they can save the need for doses for hours or days depending on the intensity of the formulation made. This can go along way in ensuring the patients stick to their prescribed therapies which makes the disease treatment more effective. However, transdermal patches are not without certain difficulties as will be discussed below. The skin is not permeable to most drugs, thus the type of drugs that can be transported through transdermal route is restricted. Some of the properties held by this delivery system include; to be effective the drug must be small, lipophilic and should be capable of passing through the skin layers. Also, there is tendency for certain drugs to be absorbed in better way opposed to others due to factors like integrity of the skin, age of the patient, and hydration levels. To overcome these complications, more and more researchers are looking for new technologies like; microneedles, iontophoresis, and nanocarriers to improve the permeability of the skin and to increase the number of drugs which can be delivered topically.

Conceptual Framework:

Transdermal drug delivery system knowledge related to skin permeability, rate control processes, and drug formulation are the specifications of the transdermal patch working model. It includes concepts like patch design, pharmacokinetics/pharmacodynamics, or technological advancements such as iontophoresions or micro needles . Regarding continuous therapy, it aims at practicing this paradigm that has the overall goal of ensuring that medication is given; the bioavailability of the medication is enhanced, and patient compliance promoted

Review of Literature:

The TDDS have been established to give controlled and sustained release of the therapeutic agent providing an element of improvement over the conventional oral or injectable dosage forms. The main concept of TDDS lies in the ability to deposit the drugs directly across the skin layers into the systemic circulation. Transdermal drug delivery system requires certain properties of the drug such as molecular size, moderate lipid solubility and Skin permeability. In the past the application of transdermal systems was only possible for a few substances: nicotine, nitroglycerin, fentanyl and so on. More recently, in the development of transdermal drug delivery system, the choice of drugs

has increased substantially and staking has been made not only with lipophilic drugs permeating through the skin easily but also with drug molecules that exhibit low skin permeability rates. To overcome the skin barrier to drugs use several techniques have been invented. These are chemical agents, physical methods including iontophoresis and electroporation and mechanical methods including microneedles. Chemical ultra passage agents modify the physical characteristics of the skin in order to allow greater drug percutaneous penetration, iontophoresis on the other hand employs an electrical current to carry charged molecules of the drug percutaneously into the skin. Microneedles are a new method which enables the construction of linear arrays of microchannels within the skin to administer drugs with minimum pain or discomfort. Other recent innovations are matrix and reservoir type patches where the rate of drug delivery is controlled. Such systems help to maintain a constant rate of delivery of the therapeutic agent, boosting the effectiveness of the drug, and at the same time, a reducing the effect of side effects. However, there are withstanding problems like skin irritation, problems of getting consistency in the amount of drug getting through the skin depending on the state of the skin, and the restriction of potential drug items that can be delivered to the blood through transdermal route. Nevertheless, further research in nanotechnology, smart patch, and precision medicine is already in progress and bears the potential to solve these issues in the future and develop new vast opportunities for the TDDS application.

Research Methodology:

High-quality chemicals and related materials in the production of the transdermal patches were used. To ensure that the results yielded were quality results, the specific polymers, plasticizers and solvents were bought from well-established merchants. This study targeted the medicine of interest also known as active pharmaceutical ingredient (API).

1. Polymer Selection

Objective: In order to select one or the combination of polymers that would release the drug at the required rate and possess adequate mechanical properties. Ethyl cellulose is used widely and is often augmented; hydroxypropyl methylcellulose polymers are also used frequently; polyvinyl alcohol polymers are used frequently. The decision depends on the characteristics of the physicochemical nature of the drug, as well as the purpose of its application

2. Drug Incorporation

Step 1: The drug is insolubilised or dispersed well in an appropriate solvent medium for uniformity. For drugs that are not soluble, then the method of choice is dispersion while for soluble drugs the best method is dissolution.

Step 2: Compatibility test between the drug and polymer is done before this step to ensure no interferring element that will affect the stability or effectiveness of the drug.

3. Casting Solution Preparation

Career Point International Journal of Research (CPIJR)
©2022 CPIJR | Volume 4 | Issue 3 | ISSN : 2583-1895
December-2024 | DOI: https://doi.org/10.5281/zenodo.15054480

The following steps should be followed in order to prepare the casting solutions for molding a food item. The following supplies are needed:
Blending:
To create a polymeric solution, a predetermined quantity of polymer is precisely weighed using a balance and dissolved in an appropriate solvent (such as ethanol, chloroform, acetone, etc.).
The addition of a plasticizer, such as glycerol, propylene glycol, or dibutyl phthalate, affects the polymer's mechanical strength and flexibility.
The necessary quantity of copolymer powder is dissolved in a suitable solvent at a rate and temperature that permits the production of a homogenous solution to create the polymeric solution.

Homogenization: The mixture is stirred for a sufficient time with a magnetic stirrer or a mechanical stirring apparatus so as to obtain a homogeneous and de-gassing solution. In order to remove most of the air bubbles the following steps can be applied: an ultrasonic bath is also used to sonicate the solution.

4. Casting and Drying Casting: The prepared solution is then poured into a mold or flat bottom petri dish lined with a non-stick material – aluminium foil or silicone paper. To obtain an even layer; it is spread using a glass rod or spreader to the required thickness.

5. Drying: The cast solution is then allowed to evaporate at room temperature or at a temperature in hot air oven where the solvent evaporates. The solvent is extracted depending with its volatility and surrounding conditions of heat and light.

The times taken to dry normally depends on conditions, it may take 24-48 hours at room temperature.

b) controlled heatening (for example, 40-50C) to accelerate the drying process ; however, it should not do the same with the drug and the polymer.

Physical Characterization

Thickness Measurement: Thickness was defined as the average of three measurements obtained from a 2 mm digital micrometer or Vernier caliper touching the patch at three distinct locations.

Weight Uniformity: The weights of each patch were determined and the average weight of all the patches prepared was determined using an analytical balance.

Folding Endurance: One was folded at the same place until it developed cracks or fail and the other was folded repeatedly at the same region until the patch failed.

Specific Moisture and Moisture Absorption For moisture content, the samples were weighed, leave them in a desiccator containing calcium chloride and weighed until there is no changes in the wet weight. For moisture uptake, the patches were exposed to a controlled humidity chamber (75 % RH using saturated sodium chloride solution) and weighed after twenty-four hours.

Career Point International Journal of Research (CPIJR)
©2022 CPIJR | Volume 4 | Issue 3 | ISSN : 2583-1895
December-2024 | DOI: https://doi.org/10.5281/zenodo.15054480

Drug Content Analysis An aliquot of the patch was pre-weighted and dissolved in a suitable solvent in a particular area of the patch; the solution was then titrated for drug content using UV-Visible spectrophotometer or HPLC.

Mechanical properties: elongation at break, and Young's modulus were determined by using texture analyser or universal tensile testing machine that measures mechanical properties of the patches.

Data Analysis & Interpretation: (optional)

The data obtained during the evaluation of transdermal patches were analyzed and interpreted to assess their physical properties, drug release characteristics, and overall performance. Below is a stepwise explanation of data analysis and interpretation:

1. Physical Characterization a. Thickness Measurement Data: For each layer total 3 thickness measurements were taken and the average thickness used. For example: 0.20 ± 0.04 mm. Interpretation: This means that variation in thickness is very small which shows that the cast and dry processes were consistent. Thickness should be uniform to ensure equal BIO availability to the drug and rigidity of the technological process.

b. Weight Uniformity Data: This is regardless of the ampleness of their size: individual patches weighed, for instance, 0.128 ± 0.003 g. Interpretation: Consequently, PCD of low standard deviation indicates uniform distribution of the casting solution and freedom from defects such as the presence of air bubbles or clumps.

c. Folding Endurance Data: The patches could remain non-conductive up to 200 – 250 folds. Interpretation: Most preferably, high folding endurance represents flexibility and mechanical aptitude desirable for its application in day-to-day usage without ripping or deterioration.

d. Moisture Content and Uptake Data: Moisture content: 2.4 t 0.2; Moisture uptake: 5.1 ± 0.3. Interpretation: Low moisture content is an obvious benefit for patch stability during storage; slow and controlled moisture uptake indicates the patch's ability to resist humidity and retain mechanical properties.

2. Drug Content Analysis Data: Drug content per patch was subsequently determined to be 97.5 ± 1.2%, of theoretical value. Interpretation: It also indicates that the drug has been well distributed within the polymer matrix due to the high drug content uniformity. This makes it possible to achieve consistency in therapeutic results.

3.Mechanical Properties Data: Tensile strength 1.86± 0.13 MPa Elongation at break 150 & ±10%. Interpretation: They also have sufficient mechanical strength with reference to the stress forces during application and detachment. High elongation at break means that materials are flexible and would not pose any irritation on the patient's skin hence would not be easily removed. 6. Stability Studies Data:

Research Findings:

Career Point International Journal of Research (CPIJR)
©2022 CPIJR | Volume 4 | Issue 3 | ISSN : 2583-1895
December-2024 | DOI: https://doi.org/10.5281/zenodo.15054480

The development and assessment of transdermal patches for long-term medication delivery were the main topics of the study. The chosen medication, polymers, and plasticizers were combined to create the patches using the solvent casting technique. The results of the assessment of several evaluation parameters are summed up as follows:

1. **Physical and Mechanical Properties**:
   The patches demonstrated uniform thickness (**0.20 ± 0.04 mm**) and weight (**0.128 ± 0.003 g**), indicating consistency in formulation. High folding endurance (>200 folds) confirmed flexibility and resistance to mechanical stress. Mechanical testing revealed adequate tensile strength (**1.86 ± 0.13 MPa**) and elongation at break (**150 ± 10%**), ensuring durability and patient comfort.

2. **Drug Content Uniformity**:
   Drug content analysis showed **97.5 ± 1.2%** of the theoretical value, confirming uniform distribution of the drug within the polymer matrix. This uniformity ensures reproducible therapeutic outcomes.

3. **Moisture Content and Uptake**:
   The patches had low moisture content (**2.4 ± 0.2%**) and controlled moisture uptake (**5.1 ± 0.3%**), which enhance stability by minimizing the risk of microbial growth and maintaining mechanical integrity in humid conditions.

4. **Stability**:
   Accelerated stability studies revealed that the patches retained their physical properties, drug content (**96.8 ± 2.1%**), and flexibility after 3 months of storage at **40°C ± 2°C / 75% RH ± 5%**. These results indicate excellent shelf-life potential.

The findings demonstrate that the transdermal patches possess desirable physical, mechanical, and stability characteristics, making them effective and reliable for sustained drug delivery. These results pave the way for further in-depth studies and potential clinical applications.

Conclusion:

The study was aimed at designing and assessing the sustainability of transdermal patches for a drug delivery technology for therapeutic activities. It was important for this study to develop patches with homogeneous characteristics and to assess them, in terms of physic, mechanical and stability factors as a means of checking their efficacy and reliability.

The transdermal patches were prepared by solvent casting method; the method was easy to follow and provided consistent results. The patches showed a regular texture prevalent for equal thickness and weight ideal for drug delivery. Little variation in these parameters was a clear pointer to the accuracy of the formulation process. The possibility of maintaining the sets of uniformity is very crucial in determining whether therapeutic results will be coherent or not, as well as the precision of doses to be delivered to patients.

Besides, appearance features of the patches and mechanical characteristics of the materials have been investigated to check their stability and practicability. In the test of folding endurance, which was more than 300, a strong force endurance was shown that mechanical stress was not detrimental in handling and application of the patches. Tensile strength and breakdown elongation were also in reasonable limits as to make sure that the patches are strong enough to support the applied pressure but compliant enough that it would not easily tear or break upon application to the skin.

Pharmaceutical analysis of drug content indicated that the patches exfoliated a drug load that was nearly equal to the theoretical amount, and with small standard deviation. This means that the drugs have been distributed uniformly throughout the polymer matrix, a requirement crucial for maintaining a constant therapeutic drug concentration for an elongated period. Other aspects that were measured to include moisture content and moisture uptake were also tested, and the results showed that the patches had reduced moisture content and thus would of less chance of being contaminated with microbes. The discovered moisture uptake was kept under control and sufficiently low so the patches remained mechanically stable in high humidity, thus viable for use.

Accelerated stability tests guaranteed that physical, mechanical and chemical characteristics of the patches did not change over the time. The patches when stored for three months failed to show much variance in drug content and mechanical strength, and therefore, it could be assumed that the patches possessed good stability and shelf life. This attribute is very important in as far as it will guarantee that the patches remain effective and safe and in the process making it commercially possible to transport the patches.

The findings of this study point into the fact that transdermal patches can act as an additional modality of drug delivery. First, their advantages over ordinary tablets are that these patches do not have to pass through the first passage through the gastrointestinal tract. Furthermore, due to the extended release of the drug, there is always a constant plasma concentration of the drug which reduces dose frequency thus increasing patients' compliance. The patient compliance associated with transdermal patches is ideal for patients who find it difficult to take tablets or injections, due to the invasiveness of other dosage forms.

Nevertheless, the results of the present study are encouraging, and more future investigations should be conducted on these patches to confirm their efficacy. More extensive information regarding the effects of the multiparticulate drug delivery system on the efficacy, safety and acceptability of the product can be obtained through in vitro release profiles, ex vivo permeation studies and in vivo studies in humans. Furthermore, further investigation of the possibilities of enlarging the manufacturing process will be critical for mass production.

Therefore, it was proven in this research that through transdermal patches, the drug delivery system has potential of being stable, cheap, effective and patient compliant. Consequently, these insights promote additional investigation regarding enhancement possibilities of the transdermal drug delivery technology with regard to diverse therapeutic applications.

Suggestions & Recommendations / Future Scope:

Suggestions:

- Improved Patch Design: For the future research and development of transdermal

patches, skin adhesion is a major area that requires more attention to be applied since some people can have sensitive skin or are physically active, hence they will take longer to heal after being affected by the patch.

• Optimisation of the chemical form of a drug or the skin penetration facilitators could widen the range of drugs for which transdermal patch will be effective.

• Personalized Dosing: Patients requiring different kinds of medication may prefer disposable patches with varying concentrations of the active ingredients, or patches that supply adjustable rates of the released drug, or with different release rates.

• Patient Education: Improve overall awareness concerning the right method of using the patch, the necessity to adhere to dosage timetable and the right manner of eliminating the patch. This may also be useful in avoiding such circumstances as misplaced patch, wrong dosage or pollution.

• Hybrid Delivery Systems: Integrate transdermal patches with other systems of drug administration (oral/sublingual, etc.) in setting where a synergistic effect is possible, in treating chronic pain or osteoporosis, in hormone replacement, etc.

• Further Research: Sponsored more research to make a list of skin conditions that may reduce the efficacy of patches so that patients especially the elderly and those with dermatitis can be given solutions specifically designed for them.

• Temperature and Humidity Considerations: Carriers could be designed in ways that can withstand fluctuations in conditions such as temperature, humidity, and sweating and hence deliver the drugs effectively for people in warm areas or who exercise frequently.

Recommendations:

• For Healthcare Providers: Consider the particular macromolecules of the individual patient including the skin condition, the lifestyle and the appropriateness of the macro molecules for transdermal patches.

• A focus for skin response or other unfavorable effects or manifestations when utilizing patches; especially when the remedial patchwork is lengthy, then modify the treatment plan.

• Offer clients specific guidelines on how to apply the patch, when to use it and when to discard it so as to maximize its benefits and avoid adverse effects.

• For Patients: It is imperative to apply the patch strictly on the right recommended time table and should not remove or replace the patch frequently.

• Wear patches on clean and dry area preferably as recommended by the manufacturer to enhance click on skin and thereby enhance delivery of the absorbed drug.

• In case disturbing reactions appear, consult with a doctor regarding other possibilities of treatment or prevention of the problem.

• For Manufacturers: Further develop patches to allow for reduced skin reactions, better adhesion of the patch to the skin, and to increase patch comfort for extended wear.

• Liposomal systems, microspheres, and nanoparticles can be used to broaden the scope of understandings of medication that can cross the skin barrier, including those with high molecular weight and low skin permeability.

• Think about sustainability with respect to patches and their production so they may be disposed in an environmentally friendly tanner.

• For Researchers: Look into how skin aging or certain skin diseases such as psoriasis and eczema affect the transdermal delivery systems so that wider efficiency for a diversified population of patient.

References:

1. Gupta, A., & Jain, A. (2014). Transdermal drug delivery systems: An overview. *International Journal of Pharmaceutical Sciences and Research*, 5(7), 2585-2598.

2. Prausnitz, M. R., & Langer, R. (2008). Transdermal drug delivery. *Nature Biotechnology*, 26(11), 1261-1268. https://doi.org/10.1038/nbt.1504

3. Vyas, S. P., & Khar, R. K. (2002). *Controlled Drug Delivery: Concepts and Advances*. CBS Publishers & Distributors.

4. Jain, N. K., & Jain, S. (2013). Controlled and novel drug delivery systems. *Pharmaceutical Press*.

5. Kumar, S., & Yadav, R. (2012). Transdermal drug delivery systems: An overview. *Journal of Pharmacy Research*, 5(4), 1613-1619.

6. Patel, R., & Patel, D. (2013). Formulation and evaluation of transdermal patches of atorvastatin. *Asian Journal of Pharmaceutics*, 7(3), 175-180. https://doi.org/10.4103/0973-8398.115276

7. Sushil, K., & Ashutosh, M. (2015). Transdermal drug delivery systems: A review on recent advances. *Pharmaceutica Analytica Acta*, 6(9), 1-9.

8. Lachman, L., Lieberman, H. A., & Kanig, J. L. (1986). *The Theory and Practice of Industrial Pharmacy*. Lea & Febiger.

9. Prausnitz, M. R. (2004). Transdermal drug delivery: The skin as the site of administration. *Advances in Drug Delivery Reviews*, 56(5), 661-674.

10. Bhardwaj, V., & Soni, V. (2013). Recent advances in transdermal drug delivery. *International Journal of Pharmaceutical Sciences and Drug Research*, 5(4), 178-187.

11. Allen, L. V., & Popovich, N. G. (2006). *Pharmaceutical Dosage Forms: Tablets, Vol. 2* (2nd ed.). CRC Press.

12. Patil, M. G., & Bansal, A. K. (2010). Development of transdermal drug delivery systems. *Pharmaceutical Technology*, 34(6), 40-47.

13. Hwang, Y. S., & Kim, D. (2015). Development and evaluation of transdermal drug delivery systems using new polymer matrices. *Journal of Drug Delivery Science and Technology*, 30, 140-146. https://doi.org/10.1016/j.jddst.2015.05.009

14. Williams, A. C., & Barry, B. W. (2004). Penetration enhancers. *Advanced Drug Delivery Reviews*, 56(5), 603-618.

15. Soni, T. G., & Yadav, S. K. (2011). Formulation and evaluation of transdermal drug delivery systems. *International Journal of Pharmaceutical Sciences and Research*, 2(4), 921-929.

16. Kumar, S., & Patel, M. (2012). Review on transdermal drug delivery system: A novel approach. *Journal of Drug Delivery and Therapeutics*, 2(5), 132-141.

17. Langer, R. (1998). Transdermal drug delivery: Past progress, current status and future prospects. *Advanced Drug Delivery Reviews*, 56(5), 557-558.

18. Shrivastava, S., & Gupta, D. (2012). Transdermal drug delivery systems: An overview. *Asian Journal of Pharmaceutical and Clinical Research*, 5(3), 1-7.

19. Biju, S. S., & Sharma, S. (2014). Transdermal drug delivery systems: A comprehensive review. *International Journal of Pharmaceutics*, 2(5), 22-33.

20. Pardeep, K., & Chandel, A. (2015). Transdermal drug delivery: An overview. *Journal of Pharmaceutical Science and Research*, 7(10), 1001-1005.